1191997-64-4

Basic information

• Product Name: (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoic acid
• Synonyms: (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoic acid;(alphaS)-4-(2-Chlorophenoxy)-2,5-dihydro-alpha-(2-methylpropyl)-2-oxo-1H-pyrrole-1-acetic acid;(S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid
• CAS NO: 1191997-64-4
• Molecular Formula: C₁₆H₁₈ClNO₄
• Molecular Weight: 324
• EINECS: -0
• Mol File: 1191997-64-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.318±0.06 g/cm3 (20 ºC 760 Torr)
• CAS DataBase Reference: (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoic acid(1191997-64-4)
• EPA Substance Registry System: (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoic acid(1191997-64-4)

Safety Data

• Hazardous Substances Data: 1191997-64-4(Hazardous Substances Data)

Usage

Description

(S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoic acid is a complex organic chemical compound characterized by the presence of a pyrrole ring, a 2-chlorophenoxy group, a 2-oxo group, and a 4-methylpentanoic acid group. This unique molecular structure suggests potential bioactivity and may endow the compound with properties that are of interest in pharmaceutical development.

Uses

Used in Pharmaceutical Industry:
(S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoic acid is used as a potential pharmaceutical agent for its structural features that are reminiscent of known drugs and bioactive molecules. (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoic acid's specific arrangement of functional groups may confer it with therapeutic properties, although further research is necessary to elucidate its exact applications, mechanisms of action, and safety profile.
Given the compound's structural complexity and the presence of a pyrrole ring, which is a common structural motif in various biologically active compounds, it may have potential applications in the development of new drugs targeting specific receptors or enzymes. The 2-chlorophenoxy group could potentially influence the compound's lipophilicity, affecting its absorption, distribution, metabolism, and excretion (ADME) properties, which are critical considerations in drug design.
The 2-oxo group may also play a role in the compound's reactivity or its ability to form hydrogen bonds, which could be important for its interaction with biological targets. The 4-methylpentanoic acid group contributes to the overall hydrophobicity of the molecule, which might affect its solubility and pharmacokinetics.

Upstream product

• 1191997-60-0 (E)-4-bromo-3-(2-chloro-phenoxy)-but-2-enoic acid ethyl ester 
• 1191997-59-7 ethyl (2E)-3-(2-chlorophenoxy)but-2-enoate 
• 95-57-8 2-monochlorophenol 
• 1191997-63-3 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid methyl ester 

Downstream Products

• 1191995-46-6 (5-{(S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoylamino}-[1,2,4]thiadiazol-3-yl)-acetic acid allyl ester 
• 1191994-99-6 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191995-48-8 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [3-(2-oxo-propyl)-[1,2,4]thiadiazol-5-yl]-amide 
• 1191995-44-4 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-amide 
• 1191995-43-3 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid (3-dimethylamino-[1,2,4]thiadiazol-5-yl)-amide 
• 1191995-41-1 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [3-(3,3,3-trifluoro-propyl)-[1,2,4]thiadiazol-5-yl]-amide 
• 1191995-40-0 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid (3-cyclopropyl-[1,2,4]thiadiazol-5-yl)-amide 
• 1191995-39-7 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [3-(2-methoxy-ethyl)-[1,2,4]thiadiazol-5-yl]-amide 
• 1191994-98-5 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-amide 
• 1191995-47-7 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid(3-methoxymethyl-[1,2,4]thiadiazol-5-yl)-amide 

Relevant articles and documents

Deuterated pyrrolidone derivative Pharmaceutical compositions and uses thereof

The invention relates to a deuterated pyrrolidone derivative and a preparation method thereof, and also relates to application of the deuterated pyrrolidone derivative and a pharmaceutical composition thereof in treatment and prevention of metabolic disorder related diseases, and belongs to the field of medicines.

PYRROLIDINONE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.